RT Journal Article
T1 D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis.
A1 Jara-Palomares, Luis
A1 Solier-Lopez, Aurora
A1 Elias-Hernandez, Teresa
A1 Asensio-Cruz, Maria Isabel
A1 Blasco-Esquivias, Isabel
A1 Sanchez-Lopez, Veronica
A1 de la Borbolla, Maria Rodriguez
A1 Arellano-Orden, Elena
A1 Suarez-Valdivia, Lionel
A1 Marin-Romero, Samira
A1 Marin-Barrera, Lucia
A1 Ruiz-Garcia, Aranzazu
A1 Montero-Romero, Emilio
A1 Navarro-Herrero, Silvia
A1 Lopez-Campos, Jose Luis
A1 Serrano-Gotarredona, Maria Pilar
A1 Praena-Fernandez, Juan Manuel
A1 Sanchez-Diaz, Jose Maria
A1 Otero-Candelera, Remedios
AB Optimal duration of anticoagulation for cancer-associated thrombosis (CAT) remains unclear. This study assessed D-dimer (DD) and high-sensitivity C-reactive protein (hs-CRP) levels after the withdrawal of anticoagulation treatment to predict the risk of venous thromboembolism (VTE) recurrence among patients with CAT. Prospective, multicentre study to evaluate CAT with ≥3 months of anticoagulation that was subsequently discontinued. Blood samples were taken when patients stopped the anticoagulation and 21 days later to determine the DD and hs-CRP levels. All patients were followed up for 6 months to detect VTE recurrence. Between 2013 and 2015, 325 patients were evaluated and 114 patients were ultimately enrolled in the study. The mean age was 62 ± 14 years and nearly 40% had metastasis. Ten patients developed VTE recurrence within 6 months (8.8%, 95% confidence interval [CI]: 4.3-15.5%). The DD and hs-CRP levels after 21 days were associated with VTE recurrence. The subdistribution hazard ratios were 9.82 for hs-CRP (95% CI: 19-52) and 5.81 for DD (95% CI: 1.1-31.7). This study identified that hs-CRP and DD were potential biomarkers of VTE recurrence after discontinuation of anticoagulation in CAT. A risk-adapted strategy could identify low-risk patients who may benefit from discontinuation of anticoagulation.
YR 2018
FD 2018-10-15
LK http://hdl.handle.net/10668/13079
UL http://hdl.handle.net/10668/13079
LA en
DS RISalud
RD Apr 4, 2025